Corbus Pharmaceuticals Holding (CRBP)
Corbus Pharmaceuticals Holding (NASDAQ: CRBP) is a clinical-stage biotechnology company focused on developing and commercializing therapies in oncology and obesity. Its pipeline includes CRB-701, an antibody-drug conjugate designed to target Nectin-4 on cancer cells and deliver a cytotoxic payload of monomethyl auristatin E, as well as CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist being developed for obesity. Founded in 2009 and headquartered in Norwood, Massachusetts, Corbus is a common stock listed on the NASDAQ exchange.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CRBP
|
$4.66
|
62.9% Upside
|
Bargain
|
$34.89 1,119.9% Upside
|
Not available
|
Bargain
|
Weak
|
0.0%
|
November 10, 2026
|
0.5x
|
55.123 M
|
-58.361 M
|
5.8%
|
72.9%
|
-8.6
|
85.1%
|
